Announcement PDF Cynata Therapeutics Limited ABN – 98 104 037 372 Level 3, 100 Cubitt Street Cremorne VIC 3121 Australia T: +613 7067 6940 E: info@cynata.com www.cynata.com ASX ANNOUNCEMENT 22 June 2026 Investor Webinar Melbourne, Australia; 22 June 2026: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, reminds shareholders that an investor webinar will be held today, Monday 22 June 2026, at 8:30am AEST, hosted by CEO and Managing Director, Dr Kilian Kelly, and Chair, Dr Geoff Brooke. Please visit the following link to register: https://cynata.com/webinars/rvJo2r-cynata-investor-webinar A copy of the presentation to be delivered during the webinar is attached to this announcement. After the webinar is complete, a recording will be available on the Company’s InvestorHub portal. -ENDS- Authorised for release by Dr Kilian Kelly, CEO & Managing Director CONTACTS: Dr Kilian Kelly, CEO & MD, Cynata Therapeutics, +61 (03) 7067 6940, kilian.kelly@cynata.com Lauren Nowak, Media Contact, +61 (0)400 434 299, investors@cynata.com About Cynata Therapeutics (ASX: CYP) Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges and limitations of conventional MSC production by using induced pluripotent stem cells (iPSCs) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the necessity to obtain tissue from multiple donors on an ongoing basis, and without the complexity and product inconsistency resulting from conventional methods. Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group. Investor Webinar: Results Update June 2026 (ASX:CYP) Important Information Summaryinformation This Presentation contains summary informationabout Cynata Therapeutics Limited and its subsidiaries (CYP, or Cynata) which is current as at 19 June 2026.This Presentation should be read in conjunctionwith CYP’s other periodic and continuousdisclosure information lodgedwiththeAustralian Securities Exchange(ASX),which areavailable at www.asx.com.au. Not an offer This Presentation is not a prospectus,product disclosure statement or other offering document under Australian law (and willnot be lodged with the ASIC) or any other law.This Presentation is for information purposes only andis not an invitationorofferof securities forsubscription,purchase or sale inanyjurisdiction.The release,publication or distributionof this Presentation (including an electroniccopy) outsideAustralia may be restricted by law. If you come into possessionof this Presentation,you should observe such restrictions.Any non-compliance with these restrictions may contravene applicable securities laws. Not investmentadvice ThisPresentation doesnot constituteinvestment or financial product advice (nor tax,accounting or legaladvice) or any recommendationbyCYP orits advisers to acquire CYPsecurities. This Presentationhas beenprepared without taking account of any person’s individual investment objectives, financial situation or particular needs. Beforemaking an investment decision, prospectiveinvestorsshouldconsider the appropriatenessof the information having regard to theirowninvestment objectives,financialsituationandneeds and seek legal, accounting and taxation advice appropriate to their jurisdiction.CYPis not licensed to provide financialproduct advicein respect of CYPsecurities. Investment risk andpast performance An investment in CYPsecuritiesis subject to known and unknownrisks,someof which are beyond the controlof CYP and its directors.CYPdoes not guaranteeanyparticular rateof returnor performanceof CYP. Past performancecannot be relied upon as an indicatorof (andprovidesno guidance as to) future CYP performanceincluding future share price performance. Financial data All financial information inthis Presentation isin Australiancurrency (A$) unlessotherwise stated.This Presentation contains historical financial information based onfinancialinformationthat has been disclosed to theASX. Any discrepancies betweentotals and sums of components in tables and figures inthis Presentation aredue torounding. Forward-looking statements This Presentation contains certain ‘forward-looking statements’, whichcan generallybeidentified by the useof forward looking words such as ‘expect’, ‘anticipate’,‘likely’, ‘intend’, ‘should’, ‘could’,‘may’,‘predict’,‘plan’, ‘propose’,‘will’, ‘believe’, ‘forecast’, ‘estimate’, ‘target’, ‘outlook’,‘guidance’,‘potential’andothersimilarexpressions.The forward looking statements contained inthis Presentation are not guaranteesor predictions of future performanceand involve known and unknown risks and uncertainties and other factors, many ofwhich are beyond the controlof CYP, its directors and management, and may involve significant elements of subjectivejudgment and assumptionsas to future events which may ormay not becorrect.There can be no assurance that actual outcomes will not differmaterially from these forward looking statements. A number ofimportant factorscould cause actualresults or performance to differ materially from the forward looking statements. No representationorwarranty, expressorimplied, is made as to the accuracy,likelihood of achievement orreasonablenessof any forecasts,prospects, returns or statements inrelation to futurematterscontained in this Presentation. The forward looking statements arebased on information availableto CYPas at thedateof this Presentation.Except asrequired bylawor regulation(including theASX Listing Rules), CYP and its directors,officers, employees,advisers, agents and intermediariesundertake no obligation to provideany additionalor updated informationwhether as aresult of new information,futureevents or results or otherwise. Youare strongly cautioned not to place undue reliance on forward-looking statements. IndustryandMarketdata Certainmarket and industry dataused inconnectionwiththis Presentation may havebeen obtained from research, surveys or studiesconducted by third parties,including industryorgeneral publications.NeitherCYPnorits representativeshaveindependentlyverified any suchmarket orindustry data provided by thirdparties orindustry or general publications. Disclaimer To themaximum extent permitted by law, CYPand its advisers,affiliates,related bodies corporate,directors, officers, partners, employees and agents (RelatedPersons) excludeand disclaim allliability, including without limitation for negligence, forany expenses, losses,damages orcosts arising fromthis Presentation orrelianceonanything contained inor omitted from it. To themaximum extent permitted by law, CYPand its Related Persons make no representation or warranty, express or implied, as to thecurrency, accuracy,reliabilityor completenessof informationin this Presentation and disclaim any obligation orundertaking toreleaseanyupdate orrevisionto the information inthis Presentation to reflect any change in expectations orassumptions. Statements madein this Presentation are made only as at the date of this Presentation. The information in this Presentation remains subject to change without notice. cynata.com 2 Two Pivotal Readouts: A surprising and disappointing outcome 3 cynata.com • This has been a verydifficult few days for the Company • Cynata reported top-line results from two pivotal trials • the Phase 2 trial of CYP-001 in acute Graft versus Host Disease (aGvHD) • and the Phase 3 SCUlpTOR trialof CYP-004 in knee osteoarthritis (OA). • Neither trial met its primary endpoint. There were no statistically significant differences between the active and control groups on the primary or keysecondarymeasures in either study. • The aGvHD outcome was particularly unexpected. Our Phase 1 trial haddelivered strongly positive efficacy signals, giving us firmgrounds for confidence thatwere not reproduced at Phase 2. • In OA, the active group achieved the pain reduction, but an unusuallystrong placebo response prevented a treatment effect frombeing demonstrated. • Both products were again confirmed to be safe and well tolerated, with adverse event profiles comparable to control. 4 cynata.com OA: Phase 3 Results Key findings: • There were no safety concerns identified, with a similar adverse event profile between groups. • There were no statistically significant differences between the active and control groups in either of the co-primary endpoints: • The proportion of participants reaching the patient-acceptable symptom state (PASS) threshold for knee pain at 24 months was 51.7% in the active group compared to 48.1% in the control group (p=0.5907). • There was an average loss of central medial femorotibial (cMFT) cartilage thickness of 0.27mm in the active group compared to 0.21mm in the control group (p=0.1453). • There was a substantial and durable reduction in knee pain intensity at all timepoints from 3-24 months compared to baseline (secondary endpoint), with an average reduction in pain score of 26.8/100 in the active group and 25.3/100 in the control group after 24 months. However, there were no significant differences between groups at any timepoint. • Analysis of additional outcome measures is ongoing and will be reported in due course 5 cynata.com aGvHD: Phase 2 Results Key Findings: • There were no safety concerns identified, with a similar adverse event profile between groups. • There were no significant differences between groups in the primary or key secondary endpoints: Thank You. Cynata Therapeutics Limited Level 3,100 Cubitt Street Cremorne VIC 3121 Australia +61 (03) 7067 6940 investors@cynata.com www.cynata.com